Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	217.56	163.89	71.41	83.08	39.48	74.98
Depreciation & Amortization	37.79	37.77	32.88	1.24	0.19	0.09
Asset Writedown & Restructuring Costs	-	-	81.51	-	-	-
Loss (Gain) From Sale of Investments	-4.33	-5.08	-3.02	0.76	-	-
Stock-Based Compensation	24.29	22.25	14.25	7.91	6.07	6.26
Other Operating Activities	0.62	-9.95	-16.11	9.33	9.6	-32.19
Change in Accounts Receivable	-48.14	-11.96	-43.08	-3.82	-0.63	4.55
Change in Inventory	-8.39	-3.9	-4.74	1.07	-3.22	-2.69
Change in Accounts Payable	-2.47	1.8	10.82	1.21	-1.49	0.14
Change in Other Net Operating Assets	17.72	44.98	-0.33	15.28	10.36	-6.11
Operating Cash Flow	234.66	239.81	143.6	116.05	60.37	45.03
Operating Cash Flow Growth	4.49%	67.00%	23.74%	92.22%	34.06%	30.11%
Capital Expenditures	-0.11	-0.56	-198.52	-10.03	-1.02	-0.01
Sale (Purchase) of Intangibles	-	-	-81.51	-	-	-
Investment in Securities	-	-	-13.47	19.24	-10	-5
Investing Cash Flow	-0.11	-0.56	-293.5	9.21	-11.02	-5.01
Issuance of Common Stock	18.78	154.52	2.79	9.57	4.1	0.76
Repurchase of Common Stock	-1.33	-0.67	-0.98	-7.14	-12.24	-0.06
Other Financing Activities	-4.43	-13.18	-12.67	-0.74	-	-
Financing Cash Flow	13.02	140.67	-10.86	1.69	-8.14	0.7
Net Cash Flow	247.56	379.92	-160.76	126.95	41.21	40.73
Free Cash Flow	234.54	239.25	-54.92	106.02	59.35	45.02
Free Cash Flow Growth	24.74%	-	-	78.63%	31.82%	30.15%
Free Cash Flow Margin	40.56%	48.66%	-13.79%	49.49%	42.14%	37.81%
Free Cash Flow Per Share	1.85	1.92	-0.48	0.95	0.55	0.42
Cash Interest Paid	0.43	1.4	0.71	-	-	-
Cash Income Tax Paid	71.9	68.45	50.46	7.67	3	2.79
Levered Free Cash Flow	181.11	201.64	-219.49	89.69	42.14	28.96
Unlevered Free Cash Flow	181.11	201.64	-219.49	89.69	42.14	28.96
Change in Working Capital	-41.28	30.91	-37.32	13.73	5.02	-4.11

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q